Real-world treatment outcomes and healthcare resource use associated with antiemetics among cancer patients on highly emetogenic platinum-based chemotherapy

Ramucirumab+docetaxel post immune checkpoint inhibitors and platinum-based chemotherapy in advanced or metastatic non-small cell lung cancer: Learnings from the TREAT-LUNG Observational Study

by | May 23, 2022 | Cancer solid tumor posters, Presentations

Abstract OBJECTIVES: Adding ramucirumab to docetaxel after failure of chemotherapy improves response rates and survival in aNSCLC. TREAT-LUNG aimed to characterize real-world use of ramucirumab+docetaxel or docetaxel, following ICIs and chemo for aNSCLC. METHODS:...